Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

125 questions · 126 findings · 14 reviews · Headline outcomes only

No studies found 29 · 23%GRADE not reported 2 · 1.6%Very low 37 · 29.4%Low 50 · 39.7%Moderate 8 · 6.3%High 0 · 0%

Rituximab/cyclosporin/prednisolone vs cyclosporin/prednisolone

Adverse events: hypotension · idiopathic steroid‐resistant nephrotic syndrome in children

It is very uncertain whether rituximab/cyclosporin/prednisolone changes adverse events: hypotension compared with cyclosporin/prednisolone (very low certainty).

1 finding from 1 review

Rituximab/cyclosporin/prednisolone vs cyclosporin/prednisolone

Adverse effects of antibiotics (skin rash) · idiopathic steroid‐resistant nephrotic syndrome in children

It is very uncertain whether rituximab/cyclosporin/prednisolone changes adverse events: skin rash compared with cyclosporin/prednisolone (very low certainty).

1 finding from 1 review

Rituximab/cyclosporin/prednisolone vs cyclosporin/prednisolone

Adverse events: mild dyspnoea · idiopathic steroid‐resistant nephrotic syndrome in children

It is very uncertain whether rituximab/cyclosporin/prednisolone changes adverse events: mild dyspnoea compared with cyclosporin/prednisolone (very low certainty).

1 finding from 1 review

Cyclosporin plus prednisolone vs prednisolone

Adverse effects: number needing cytotoxic agents · SSNS in children

It is very uncertain whether cyclosporin plus prednisolone changes adverse effects: number needing cytotoxic agents compared with prednisolone alone (very low certainty).

1 finding from 1 review

Oral immunosuppressants: oral cyclosporin vs topical betamethasone dipropionate

Primary: investigator‐rated good/excellent control of symptoms · people with hand eczema, continuously for 6 months, significant disability, inadequate response to conventional treatment, confirmation by…

Oral immunosuppressants: oral cyclosporin showed no clear difference in primary: investigator‐ rated good/excellent control of symptomsb compared with topical betamethasone dipropionate (moderate certainty).

1 finding from 1 review

Oral immunosuppressants: oral cyclosporin vs topical betamethasone dipropionate

Primary: participant‐rated good/excellent control of symptoms · people with hand eczema, continuously for 6 months, significant disability, inadequate response to conventional treatment, confirmation by…

Oral immunosuppressants: oral cyclosporin showed no clear difference in primary: participant‐rated good/excellent control of symptomsb compared with topical betamethasone dipropionate (moderate certainty).

1 finding from 1 review

Oral immunosuppressants: oral cyclosporin vs topical betamethasone dipropionate

Number of participants with any adverse event (primary tolerability outcome) · people with hand eczema, continuously for 6 months, significant disability, inadequate response to conventional treatment, confirmation by…

Oral immunosuppressants: oral cyclosporin showed no clear difference in primary: adverse events ‐ at least 1 adverse event compared with topical betamethasone dipropionate (moderate certainty).

1 finding from 1 review